.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
US Army
Queensland Health
AstraZeneca
QuintilesIMS
Mallinckrodt
Express Scripts
Novartis
Cerilliant
Fuji

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Substituted triazolopyridines
Abstract: The present invention relates to substituted triazolopyridine compounds of general formula (I): in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease of uncontrolled cell growth, proliferation and/or survival as well as to the use of intermediate compounds for the preparation of said compounds. ##STR00001##
Inventor(s): Schulze; Volker (OT Bergfelde, DE), Kosemund; Dirk (Berlin, DE), Schirok; Hartmut (Langenfeld, DE), Bader; Benjamin (Berlin, DE), Lienau; Philip (Berlin, DE), Wengner; Antje Margret (Berlin, DE), Briem; Hans (Berlin, DE), Holton; Simon (Berlin, DE), Siemeister; Gerhard (Berlin, DE), Prechtl; Stefan (Berlin, DE), Koppitz; Marcus (Berlin, DE), Stockigt; Detlef (Potsdam, DE), Prien; Olaf (Berlin, DE)
Assignee: Bayer Intellectual Property GmbH (Monheim, DE)
Application Number:13/704,859
Patent Claims:1. A compound of general formula (I): ##STR00229## in which: R.sup.1 represents an aryl or heteroaryl group which is substituted, one or more times, identically or differently, with a substituent selected from: R.sup.6--(C.sub.1-C.sub.6-alkyl)-, R.sup.6--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.m--, R.sup.6--(C.sub.1-C.sub.6-alkoxy)-, R.sup.6--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.p--O--, R.sup.6--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-, R.sup.6--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-O--, R.sup.6--O--, --C(.dbd.O)R.sup.6, --C(.dbd.O)O--R.sup.6, --OC(.dbd.O)--R.sup.6, --N(H)C(.dbd.O)R.sup.6, --N(R.sup.7)C(.dbd.O)R.sup.6, --N(H)C(.dbd.O)NR.sup.6R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.6R.sup.7, --NR.sup.6R.sup.7, --C(.dbd.O)N(H)R.sup.6, --C(.dbd.O)NR.sup.6R.sup.7, R.sup.6--S--, R.sup.6--S(.dbd.O)--, R.sup.6--S(.dbd.O).sub.2--, --N(H)S(.dbd.O)R.sup.6, --N(R.sup.7)S(.dbd.O)R.sup.6, --S(.dbd.O)N(H)R.sup.6, --S(.dbd.O)NR.sup.6R.sup.7, --N(H)S(.dbd.O).sub.2R.sup.6, --N(R.sup.7)S(.dbd.O).sub.2R.sup.6, --S(.dbd.O).sub.2N(H)R.sup.6, --S(.dbd.O).sub.2NR.sup.6R.sup.7, --S(.dbd.O)(.dbd.NR.sup.6)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.6, --N.dbd.S(.dbd.O)(R.sup.6)R.sup.7; and which is optionally substituted, one or more times, identically or differently, with a substituent R.sup.xy selected from: halo-, hydroxyl-, cyano-, nitro-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, hydroxy-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, R.sup.8--(C.sub.1-C.sub.6-alkyl)-, R.sup.8--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.m--, R.sup.8--(C.sub.1-C.sub.6-alkoxy)-, R.sup.8--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.p--O--, R.sup.8--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-, R.sup.8--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-O--, R.sup.8--O--, --C(.dbd.O)R.sup.8, --C(.dbd.O)O--R.sup.8, --OC(.dbd.O)--R.sup.8, --N(H)C(.dbd.O)R.sup.8, --N(R.sup.7)C(.dbd.O)R.sup.8, --N(H)C(.dbd.O)NR.sup.8R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.8R.sup.7, --NR.sup.8R.sup.7, --C(.dbd.O)N(H)R.sup.8, --C(.dbd.O)NR.sup.8R.sup.7, R.sup.8--S--, R.sup.8--S(.dbd.O)--, R.sup.8--S(.dbd.O).sub.2--, --N(H)S(.dbd.O)R.sup.8, --N(R.sup.7)S(.dbd.O)R.sup.8, --S(.dbd.O)N(H)R.sup.8, --S(.dbd.O)NR.sup.8R.sup.7, --N(H)S(.dbd.O).sub.2R.sup.8, --N(R.sup.7)S(.dbd.O).sub.2R.sup.8, --S(.dbd.O).sub.2N(H)R.sup.8, --S(.dbd.O).sub.2NR.sup.8R.sup.7, --S(.dbd.O)(.dbd.NR.sup.8)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.8, --N.dbd.S(.dbd.O)(R.sup.8)R.sup.7; R.sup.2 represents an aryl group or heteroaryl group which is substituted, one or more times, identically or differently, with a substituent selected from: R.sup.9--, R.sup.9--(C.sub.1-C.sub.6-alkyl)-, R.sup.9--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.m--, R.sup.9--(C.sub.1-C.sub.6-alkoxy)-, R.sup.9--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.p--O--, R.sup.9--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-, R.sup.9--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-O--, --O--(CH.sub.2).sub.n--C(.dbd.O)NR.sup.9R.sup.7, R.sup.9--O--, --C(.dbd.O)R.sup.9, --C(.dbd.O)O--R.sup.9, --OC(.dbd.O)--R.sup.9, --N(H)C(.dbd.O)R.sup.9, --N(R.sup.7)C(.dbd.O)R.sup.9, --N(H)C(.dbd.O)NR.sup.9R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.9R.sup.7, --NR.sup.9R.sup.7, --C(.dbd.O)N(H)R.sup.9, --C(.dbd.O)NR.sup.9R.sup.7, R.sup.9--S--, R.sup.9--S(.dbd.O)--, R.sup.9--S(.dbd.O).sub.2--, --N(H)S(.dbd.O)R.sup.9, --N(R.sup.7)S(.dbd.O)R.sup.9, --S(.dbd.O)N(H)R.sup.9, --S(.dbd.O)NR.sup.9R.sup.7, --N(H)S(.dbd.O).sub.2R.sup.9, --N(R.sup.7)S(.dbd.O).sub.2R.sup.9, --S(.dbd.O).sub.2N(H)R.sup.9, --S(.dbd.O).sub.2NR.sup.9R.sup.7, --S(.dbd.O)(.dbd.NR.sup.9)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.9, --N.dbd.S(.dbd.O)(R.sup.9)R.sup.7; and which is optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-, hydroxyl-, cyano-, nitro-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, hydroxy-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, R.sup.8--(C.sub.1-C.sub.6-alkyl)-, R.sup.8--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sup.m--, R.sup.8--(C.sub.1-C.sub.6-alkoxy)-, R.sup.8--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.p--O--, R.sup.8--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-, R.sup.8--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-O--, --O--(CH.sub.2).sub.n--C(.dbd.O)NR.sup.8R, R.sup.8--O--, --C(.dbd.O)R.sup.8, --C(.dbd.O)O--R.sup.8, --OC(.dbd.O)--R.sup.8, --N(H)C(.dbd.O)R.sup.8, --N(R.sup.7)C(.dbd.O)R.sup.8, --N(H)C(.dbd.O)NR.sup.8R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.8R.sup.7, --NR.sup.8R.sup.7, --C(.dbd.O)N(H)R.sup.8, --C(.dbd.O)NR.sup.8R.sup.7, R.sup.8--S--, R.sup.8--S(.dbd.O)--, R.sup.8--S(.dbd.O).sub.2--, --N(H)S(.dbd.O)R.sup.8, --N(R.sup.7)S(.dbd.O)R.sup.8, --S(.dbd.O)N(H)R.sup.8, --S(.dbd.O)NR.sup.8R.sup.7, --N(H)S(.dbd.O).sub.2R.sup.8, --N(R.sup.7)S(.dbd.O).sub.2R.sup.8, --S(.dbd.O).sub.2N(H)R.sup.8, --S(.dbd.O).sub.2NR.sup.8R.sup.7, --S(.dbd.O)(.dbd.NR.sup.8)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.8, --N.dbd.S(.dbd.O)(R.sup.8)R.sup.7; R.sup.3 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, nitro-, C.sub.1-C.sub.4-alkyl-, halo-C.sub.1-C.sub.4-alkyl-, C.sub.1-C.sub.4-alkoxy-, halo-C.sub.1-C.sub.4-alkoxy-, hydroxy-C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-alkoxy-C.sub.1-C.sub.4-alkyl-, halo-C.sub.1-C.sub.4-alkoxy-C.sub.1-C.sub.4-alkyl-, C.sub.2-C.sub.6-alkenyl-, C.sub.2-C.sub.6-alkynyl-, halo-C.sub.2-C.sub.6-alkenyl-, halo-C.sub.2-C.sub.6-alkynyl-, C.sub.3-C.sub.6-cycloalkyl-, or halo-C.sub.3-C.sub.6-cycloalkyl-group; R.sup.4 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, nitro-, C.sub.1-C.sub.4-alkyl-, halo-C.sub.1-C.sub.4-alkyl-, C.sub.1-C.sub.4-alkoxy-, halo-C.sub.1-C.sub.4-alkoxy-, hydroxy-C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-alkoxy-C.sub.1-C.sub.4-alkyl-, halo-C.sub.1-C.sub.4-alkoxy-C.sub.1-C.sub.4-alkyl-, C.sub.2-C.sub.6-alkenyl-, C.sub.2-C.sub.6-alkynyl-, halo-C.sub.2-C.sub.6-alkenyl-, halo-C.sub.2-C.sub.6-alkynyl-, C.sub.3-C.sub.6-cycloalkyl-, or halo-C.sub.3-C.sub.6-cycloalkyl-group; R.sup.5 represents a hydrogen atom; R.sup.6 represents a group selected from: C.sub.3-C.sub.6-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, aryl-, heteroaryl-, --(CH.sub.2).sub.q--(C.sub.3-C.sub.6-cycloalkyl), --(CH.sub.2).sub.q-(3- to 10-membered heterocycloalkyl), --(CH.sub.2).sub.q-aryl, or --(CH.sub.2).sub.q-heteroaryl; said group being optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-, hydroxyl-, cyano-, nitro-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, hydroxy-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, R.sup.8--(C.sub.1-C.sub.6-alkyl)-, R.sup.8--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.m--, R.sup.8--(C.sub.1-C.sub.6-alkoxy)-, R.sup.8--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.p--O--, R.sup.8--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-, R.sup.8--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-O--, aryl-, R.sup.8--O--, --C(.dbd.O)R.sup.8, --C(.dbd.O)O--R.sup.8, --OC(.dbd.O)--R.sup.8, --N(H)C(.dbd.O)R.sup.8, --N(R.sup.7)C(.dbd.O)R.sup.8, --N(H)C(.dbd.O)NR.sup.8R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.8R.sup.7, --NR.sup.8R.sup.7, --C(.dbd.O)N(H)R.sup.8, --C(.dbd.O)NR.sup.8R.sup.7, R.sup.8--S--, R.sup.8--S(.dbd.O)--, R.sup.8--S(.dbd.O).sub.2--, --N(H)S(.dbd.O)R.sup.8, --N(R.sup.7)S(.dbd.O)R.sup.8, --S(.dbd.O)N(H)R.sup.8, --S(.dbd.O)NR8R.sup.7, --N(H)S(.dbd.O).sub.2R.sup.8, --N(R.sup.7)S(.dbd.O).sub.2R.sup.8, --S(.dbd.O).sub.2N(H)R.sup.8, --S(.dbd.O).sub.2NR.sup.8R.sup.7, --S(.dbd.O)(.dbd.NR.sup.8)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.8, --N.dbd.S(.dbd.O)(R.sup.8)R.sup.7; R.sup.7 represents a hydrogen atom, a C.sub.1-C.sub.6-alkyl-, or C.sub.3-C.sub.6-cycloalkyl-group; or R.sup.6 and R.sup.7, together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl-group, which is optionally substituted, one or more times, identically or differently, with halogen, hydroxy, cyano-, nitro-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, hydroxy-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, C.sub.2-C.sub.6-alkenyl-, C.sub.2-C.sub.6-alkynyl- or C.sub.3-C.sub.6-cycloalkyl-; R.sup.8 represents a hydrogen atom or a C.sub.1-C.sub.6-alkyl-group; R.sup.9 represents a group selected from: C.sub.7-C.sub.10-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, aryl-, heteroaryl-; said group being optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-, hydroxyl-, cyano-, nitro-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, hydroxy-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, --(CH.sub.2).sub.q--(C.sub.3-C.sub.6-cycloalkyl), R.sup.8--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.m--, R.sup.8--(C.sub.1-C.sub.6-alkoxy)-, R.sup.8--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.p--O--, R.sup.8--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-, R.sup.8--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-O--, aryl-, R.sup.8--O--, --C(.dbd.O)R.sup.8, --C(.dbd.O)O--R.sup.8, --OC(.dbd.O)--R.sup.8, --N(H)C(.dbd.O)R.sup.8, --N(R.sup.7)C(.dbd.O)R.sup.8, --N(H)C(.dbd.O)NR.sup.8R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.8R.sup.7, --NR.sup.8R.sup.7, --C(.dbd.O)N(H)R.sup.8, --C(.dbd.O)NR.sup.8R.sup.7, R.sup.8--S--, R.sup.8--S(.dbd.O)--, R.sup.8--S(.dbd.O).sub.2--, --N(H)S(.dbd.O)R.sup.8, --N(R.sup.7)S(.dbd.O)R.sup.8, --S(.dbd.O)N(H)R.sup.8, --S(.dbd.O)NR.sup.8R.sup.7, --N(H)S(.dbd.O).sub.2R.sup.8, --N(R.sup.7)S(.dbd.O).sub.2R.sup.8, --S(.dbd.O).sub.2N(H)R.sup.8, --S(.dbd.O).sub.2NR.sup.8R.sup.7, --S(.dbd.O)(.dbd.NR.sup.8)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.8, --N.dbd.S(.dbd.O)(R.sup.8)R.sup.7; or R.sup.9 and R.sup.7, together with the nitrogen atom to which they are attached, represent a 3- to 10-memberered heterocycloalkyl-group, which is optionally substituted, one or more times, identically or differently, with halogen, hydroxy, cyano-, nitro-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, hydroxy-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl-, C.sub.2-C.sub.6-alkenyl-, C.sub.2-C.sub.6-alkynyl-, --C(.dbd.O)O--R.sup.8 or C.sub.3-C.sub.6-cycloalkyl-; n, m, p represent, independently from each other, an integer of 0, 1, 2, 3, 4, or 5; q represents an integer of 0, 1, 2 or 3; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

2. The compound according to claim 1, wherein: R.sup.1 represents an aryl or heteroaryl group which is substituted, one or more times, identically or differently, with a substituent selected from: R.sup.6--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.m--, R.sup.6--(C.sub.1-C.sub.6-alkoxy)-, R.sup.6--(CH.sub.2).sub.n(CHOH)(CH.sub.2).sub.p--O--, R.sup.6--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-, R.sup.6--(C.sub.1-C.sub.6-alkoxy-C.sub.1-C.sub.6-alkyl)-O--, R.sup.6--O--, --C(.dbd.O)R.sup.6, --C(.dbd.O)O--R.sup.6, --OC(.dbd.O)--R.sup.6, --N(H)C(.dbd.O)R.sup.6, --N(R.sup.7)C(.dbd.O)R.sup.6, --N(H)C(.dbd.O)NR.sup.6R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.6R.sup.7, --NR.sup.6R.sup.7, --C(.dbd.O)N(H)R.sup.6, --C(.dbd.O)NR.sup.6R.sup.7, R.sup.6--S--, R.sup.6--S(.dbd.O)--, R.sup.6--S(.dbd.O).sub.2--, --N(H)S(.dbd.O)R.sup.6, --N(R.sup.7)S(.dbd.O)R.sup.6, --S(.dbd.O)N(H)R.sup.6, --S(.dbd.O)NR.sup.6R.sup.7, --N(H)S(.dbd.O).sub.2R.sup.6, --N(R.sup.7)S(.dbd.O).sub.2R.sup.6, --S(.dbd.O).sub.2N(H)R.sup.6, --S(.dbd.O).sub.2NR.sup.6R.sup.7, --S(.dbd.O)(.dbd.NR.sup.6)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.6, --N.dbd.S(.dbd.O)(R.sup.6)R.sup.7; and which is optionally substituted, one or more times, identically or differently, with a substituent R.sup.xy selected from: halo-, hydroxyl-, cyano-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, hydroxy-C.sub.1-C.sub.6-alkyl-, --N(H)C(.dbd.O)R.sup.8, --N(R.sup.7)C(.dbd.O)R.sup.8, --C(.dbd.O)N(H)R.sup.8, --C(.dbd.O)NR.sup.8R.sup.7; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

3. The compound according to claim 1, wherein: R.sup.2 represents an aryl group or heteroaryl group which is substituted, one or more times, identically or differently, with a substituent selected from: R.sup.9--, R.sup.9--(C.sub.1-C.sub.6-alkyl)-, R.sup.9--(C.sub.1-C.sub.6-alkoxy)-, R.sup.9--O--, --C(.dbd.O)R.sup.9, --N(H)C(.dbd.O)R.sup.9, --N(R.sup.7)C(.dbd.O)R.sup.9, --N(H)C(.dbd.O)NR.sup.9R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.9R.sup.7, --NR.sup.9R.sup.7, C(.dbd.O)N(H)R.sup.9, --C(.dbd.O)NR.sup.9R.sup.7, R.sup.9--S(.dbd.O)--, R.sup.9--S(.dbd.O).sub.2--, --N(H)S(.dbd.O).sub.2R.sup.9, N(R.sup.7)S(.dbd.O).sub.2R.sup.9, --S(.dbd.O).sub.2N(H)R.sup.9, --S(.dbd.O).sub.2NR.sup.9R.sup.7, --S(.dbd.O)(.dbd.NR.sup.9)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.9; and which is optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-, hydroxyl-, cyano-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, --C(.dbd.O)R.sup.8, --C(.dbd.O)O--R.sup.8, --OC(.dbd.O)--R.sup.8, --N(H)C(.dbd.O)R.sup.8, --N(R.sup.7)C(.dbd.O)R.sup.8, --N(H)C(.dbd.O)NR.sup.8R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.8R.sup.7, --NR.sup.8R.sup.7, --C(.dbd.O)N(H)R.sup.8, --C(.dbd.O)NR.sup.8R.sup.7, R.sup.8--S--, R.sup.8--S(.dbd.O)--, R.sup.8--S(.dbd.O).sub.2--, --N(R.sup.7)S(.dbd.O).sub.2R.sup.8, --S(.dbd.O).sub.2N(H)R.sup.8, --S(.dbd.O).sub.2NR.sup.8R.sup.7, --S(.dbd.O)(.dbd.NR.sup.8)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.8; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

4. The compound according to claim 1, wherein: R.sup.3 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, C.sub.1-C.sub.4-alkyl-, hydroxy-C.sub.1-C.sub.4-alkyl or C.sub.2-C.sub.6-alkynyl-group; R.sup.4 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, C.sub.1-C.sub.4-alkyl-, hydroxy-C.sub.1-C.sub.4-alkyl or C.sub.2-C.sub.6-alkynyl-group; R.sup.6 represents a group selected from: --(CH.sub.2).sub.q--(C.sub.3-C.sub.6-cycloalkyl), --(CH.sub.2).sub.q-(3- to 10-membered heterocycloalkyl), --(CH.sub.2).sub.q-aryl, or --(CH.sub.2).sub.q-heteroaryl; said group being optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy- or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

5. The compound according to claim 1, wherein: R.sup.1 represents an aryl group which is substituted, one or more times, identically or differently, with a substituent selected from: --C(.dbd.O)R.sup.6, --C(.dbd.O)O--R.sup.6, --OC(.dbd.O)--R.sup.6, --N(H)C(.dbd.O)R.sup.6, --C(.dbd.O)N(H)R.sup.6, --C(.dbd.O)NR.sup.6R.sup.7, R.sup.6--S(.dbd.O)--, R.sup.6--S(.dbd.O).sub.2--, --N(H)S(.dbd.O).sub.2R.sup.6, --S(.dbd.O).sub.2N(H)R.sup.6, --S(.dbd.O)(.dbd.NR.sup.6)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.6; and which is optionally substituted, one or more times, identically or differently, with a substituent R.sup.xy selected from: halo-, hydroxyl-, cyano-, C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, hydroxy-C.sub.1-C.sub.6-alkyl-, --N(H)C(.dbd.O)R.sup.8, --N(R.sup.7)C(.dbd.O)R.sup.8, --C(.dbd.O)N(H)R.sup.8, --C(.dbd.O)NR.sup.8R.sup.7; R.sup.2 represents an aryl group or heteroaryl group which is substituted, one or more times, identically or differently, with a substituent selected from: R.sup.9--, R.sup.9--(C.sub.1-C.sub.6-alkyl)-, R.sup.9--(C.sub.1-C.sub.6-alkoxy)-, --C(.dbd.O)R.sup.9, --N(H)C(.dbd.O)R.sup.9, --N(R.sup.7)C(.dbd.O)R.sup.9, --N(H)C(.dbd.O)NR.sup.9R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.9R.sup.7, --NR.sup.9R.sup.7, --C(.dbd.O)N(H)R.sup.9, --C(.dbd.O)NR.sup.9R.sup.7, R.sup.9--S(.dbd.O)--, R.sup.9--S(.dbd.O).sub.2--, --N(H)S(.dbd.O).sub.2R.sup.9, --N(R.sup.7)S(.dbd.O).sub.2R.sup.9, --S(.dbd.O).sub.2N(H)R.sup.9, --S(.dbd.O).sub.2NR.sup.9R.sup.7, --S(.dbd.O)(.dbd.NR.sup.9)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.9; and which is optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-, hydroxyl-, cyano-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, --C(.dbd.O)R.sup.8, --C(.dbd.O)O--R.sup.8, --OC(.dbd.O)--R.sup.8, --N(H)C(.dbd.O)R.sup.8, --N(R.sup.7)C(.dbd.O)R.sup.8, --N(H)C(.dbd.O)NR.sup.8R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.8R.sup.7, --NR.sup.8R.sup.7, --C(.dbd.O)N(H)R.sup.8, --C(.dbd.O)NR.sup.8R.sup.7, R.sup.8--S(.dbd.O)--, R.sup.8--S(.dbd.O).sub.2--, --N(R.sup.7)S(.dbd.O).sub.2R.sup.8, --S(.dbd.O).sub.2N(H)R.sup.8, --S(.dbd.O).sub.2NR.sup.8R.sup.7, --S(.dbd.O)(.dbd.NR.sup.8)R.sup.7, --S(.dbd.O)(.dbd.NR.sup.7)R.sup.8; R.sup.3 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, C.sub.1-C.sub.4-alkyl-, hydroxy-C.sub.1-C.sub.4-alkyl or C.sub.2-C.sub.6-alkynyl-group; R.sup.4 represents a hydrogen atom, a halogen atom, a hydroxy-, amino, cyano-, C.sub.1-C.sub.4-alkyl-, hydroxy-C.sub.1-C.sub.4-alkyl or C.sub.2-C.sub.6-alkynyl-group; R.sup.5 represents a hydrogen atom; R.sup.6 represents a group selected from: C.sub.3-C.sub.6-cycloalkyl-, --(CH.sub.2).sub.q--(C.sub.3-C.sub.6-cycloalkyl), --(CH.sub.2).sub.q-(3- to 10-membered heterocycloalkyl), --(CH.sub.2).sub.q-aryl, or --(CH.sub.2).sub.q-heteroaryl; said group being optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-; R.sup.7 represents a hydrogen atom or a C.sub.1-C.sub.6-alkyl-group; or R.sup.6 and R.sup.7, together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl-group, which is optionally substituted, one or more times, identically or differently, with halogen, hydroxy, cyano-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy- or C.sub.3-C.sub.6-cycloalkyl-; R.sup.8 represents a hydrogen atom or a C.sub.1-C.sub.6-alkyl-group; R.sup.9 represents a group selected from: C.sub.7-C.sub.10-cycloalkyl-, 3- to 10-membered heterocycloalkyl-, heteroaryl-; said group being optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-, hydroxyl-, cyano-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, hydroxy-C.sub.1-C.sub.6-alkyl-, --(CH.sub.2).sub.q--(C.sub.3-C.sub.6-cycloalkyl), --C(.dbd.O)R.sup.8, --C(.dbd.O)O--R.sup.8, --N(H)C(.dbd.O)R.sup.8, --N(H)C(.dbd.O)NR.sup.8R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.8R.sup.7, --NR.sup.8R.sup.7, --C(.dbd.O)N(H)R.sup.8, --C(.dbd.O)NR.sup.8R.sup.7, R.sup.8--S(.dbd.O)-- or R.sup.8--S(.dbd.O).sub.2--; or R.sup.9 and R.sup.7, together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl-group, which is optionally substituted, one or more times, identically or differently, with halogen, hydroxy, cyano-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, --C(.dbd.O)O--R.sup.8 or C.sub.3-C.sub.6-cycloalkyl; q represents an integer of 0, 1, 2 or 3; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

6. The compound according to claim 1, wherein: R.sup.1 represents a phenyl group which is substituted, one or more times, identically or differently, with a substituent selected from: --N(H)C(.dbd.O)R.sup.6 or --C(.dbd.O)N(H)R.sup.6; and which is optionally substituted, one time with a substituent R.sup.xy selected from: halo-, cyano-, C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-; R.sup.2 represents a phenyl or pyridyl group which is substituted, one or more times, identically or differently, with a substituent selected from: R.sup.9--, --C(.dbd.O)R.sup.9, --N(H)C(.dbd.O)R.sup.9, --N(R.sup.7)C(.dbd.O)R.sup.9, --N(H)C(.dbd.O)NR.sup.9R.sup.7, --N(R.sup.7)C(.dbd.O)NR.sup.9R.sup.7, --NR.sup.9R.sup.7, --C(.dbd.O)N(H)R.sup.9 or --C(.dbd.O)NR.sup.9R.sup.7; and which is optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-, hydroxyl-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-; R.sup.3 represents a hydrogen atom; R.sup.4 represents a hydrogen atom; R.sup.5 represents a hydrogen atom; R.sup.6 represents a group selected from: C.sub.3-C.sub.6-cycloalkyl-, --(CH.sub.2).sub.q--(C.sub.3-C.sub.6-cycloalkyl) or --(CH.sub.2).sub.q-aryl; said group being optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-; R.sup.7 represents a hydrogen atom; R.sup.8 represents a hydrogen atom or a C.sub.1-C.sub.6-alkyl-group; R.sup.9 represents a group selected from: C.sub.7-C.sub.10-cycloalkyl-, 3- to 10-membered heterocycloalkyl-; said group being optionally substituted, one or more times, identically or differently, with a substituent selected from: halo-, hydroxyl-, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, hydroxy-C.sub.1-C.sub.6-alkyl-, --(CH.sub.2).sub.q--(C.sub.3-C.sub.6-cycloalkyl), --C(.dbd.O)R.sup.8, --C(.dbd.O)O--R.sup.8; or R.sup.9 and R.sup.7, together with the nitrogen atom to which they are attached, represent a 3- to 10-membered heterocycloalkyl-group, which is optionally substituted, one or more times, identically or differently, with halogen, hydroxy, C.sub.1-C.sub.6-alkyl-, halo-C.sub.1-C.sub.6-alkyl-, C.sub.1-C.sub.6-alkoxy-, halo-C.sub.1-C.sub.6-alkoxy-, --C(.dbd.O)O--R.sup.8 or C.sub.3-C.sub.6-cycloalkyl-; q represents an integer of 1 or 2; or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

7. The compound according to claim 1, which is selected from the group consisting of: 2-cyclopropyl-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}- [1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide, 2-cyclopropyl-N-[4-(2-{[2-ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[- 1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide, 2-cyclopropyl-N-[4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}- [1, 2,4]triazolo[1,5-a] pyridin-6-yl)phenyl]acetamide trifluoroacetate, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]a- mino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide, N-[4-(2-{[2-ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,4]triazolo- [1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide, N-[4-(2-{[4-(4,4-dimethyl-4,5-dihydro-1, 3-oxazol-2-yl)-2-methoxyphenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)p- henyl]-2-(4-fluorophenyl)acetamide, 2-(4-fluorophenyl)-N-{4-[2-({2-methoxy-4-[(4-methylpiperazin-1-yl)carbony- l] phenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl}acetamide, tert-butyl 4-(3-ethoxy-4-{[6-(4-{[(4-fluorophenyl)acetyl]amino}phenyl)[1,2,4]triazol- o[1,5-a]pyridin-2-yl]amino}benzoyl)piperazine-1-carboxylate, N-[4-(2-{[2-ethoxy-4-(piperazin-1-ylcarbonyl)phenyl]amino}[1,2,4]triazolo- [1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide, N-(4-{2-[(4-{[4-(cyclopropylmethyl)piperazin-1-yl]carbonyl}-2-ethoxypheny- l)amino] [1,2,4]triazolo[1,5-a]pyridin-6-yl}phenyl)-2-(4-fluorophenyl)acet- amide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)ph- enyl]amino}[1, 2,4]triazolo[1,5-a] pyridin-6-yl)phenyl]acetamide trifluoroacetate, 2-(4-fluorophenyl)-N-[4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(2,2,2-trifluor- oethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide, N-(cyclopropylmethyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]a- mino}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)benzamide, N-(cyclopropylmethyl)-4-(2-{[2-ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]am- ino}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)benzamide, N-(cyclopropylmethyl)-4-(2-{[4-(4,4-dimethyl-4, 5-dihydro-1, 3-oxazol-2-yl)-2-methoxyphenyl]amino}[1, 2,4]triazolo[1, 5-a]pyridin-6-yl)benzamide, 4-[(6-{4-[(cyclopropylmethyl)carbamoyl]phenyl}[1,2,4]triazolo[1,5-a]pyrid- in-2-yl)amino]-3-ethoxy-N-(1-methylpiperidin-4-yl)benzamide, N-(cyclopropylmethyl)-4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]a- mino}[1, 2,4]triazolo[1,5-a] pyridin-6-yl)benzamide trifluoroacetate, N-(cyclopropylmethyl)-4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(2,2,2-trifluor- oethoxy)phenyl]amino}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)benzamide, N-(4-Fluorbenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino- }[1,2,4]triazolo[1, 5-a]pyridin-6-yl)benzamid, 4-(2-{[2-Ethoxy-4-(morpholin-4-ylcarbonyl)phenyl}amino[1,2,4]triazolo[1,5- -a]pyridin-6-yl)-N-(4-fluorbenzyl)benzamid, 2-(4-fluorophenyl)-N-[4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(trifluorometho- xy)phenyl]amino}[1,2,4]triazolo[1,5-a] pyridin-6-yl)phenyl]acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)pheny- l]amino}[1, 2,4]triazolo[1,5-a] pyridin-6-yl)phenyl]acetamide, N-[4-(2-{[2-ethoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]amino}[1,2,4]triaz- olo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[4-methyl-6-(2-oxo-1, 3-oxazolidin-3-yl)pyridin-3-yl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)p- henyl]acetamide, N-[4-(2-{[4-(4,5-dihydro-1,3-oxazol-2-yl)-2-methoxyphenyl]amino}[1,2,4]tr- iazolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide, N-[4-(2-{[4-(4,5-dihydro-1,3-oxazol-2-yl)-2-methylphenyl]amino}[1,2,4]tri- azolo[1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide, 2-(4-fluorophenyl)-N-{4-[2-({2-methoxy-4-[(1 S,4S)-2-oxa-5-azabicyclo[2.2.1] hept-5-ylcarbonyl] phenyl}amino)[1,2,4]triazolo[1, 5-a]pyridin-6-yl]phenyl}acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylc- arbonyl)phenyl]amino}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)phenyl]acetamide, N-{4-[2-({4-[(1,1-dioxidothiomorpholin-4-yl)carbonyl]-2-methoxyphenyl}ami- no)[1,2,4]triazolo[1, 5-a]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)acetamide, 2-(4-fluorophenyl)-N-{4-[2-({4-[(3-hydroxyazetidin-1-yl)carbonyl]-2-metho- xyphenyl}amino)[1,2,4]triazolo[1, 5-a]pyridin-6-yl]phenyl}acetamide, 2-(4-fluorophenyl)-N-{4-[2-({4-[(4-hydroxypiperidin-1-yl)carbonyl]-2-meth- oxyphenyl}amino)[1, 2,4]triazolo[1, 5-a]pyridin-6-yl]phenyl}acetamide, 4-{[6-(4-{[(4-fluorophenyl)acetyl]amino}phenyl)[1,2,4]triazolo[1,5-a]pyri- din-2-yl]amino}-3-methoxy-N-(oxetan-3-yl)benzamide, N-[4-(2-{[4-(azetidin-1-ylcarbonyl)-2-methoxyphenyl]amino}[1,2,4]triazolo- [1,5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide, N-[4-(2-{[2-ethoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino- }[1,2,4]triazolo[1, 5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide, N-{4-[2-({2-ethoxy-4-[(3-hydroxyazetidin-1-yl)carbonyl] phenyl}amino)[1, 2,4]triazolo[1,5-a]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)acetamide, 3-ethoxy-4-{[6-(4-{[(4-fluorophenyl)acetyl]amino}phenyl)[1,2,4]triazolo[1- ,5-a] pyridin-2-yl]amino}-N-(1-methylpiperidin-4-yl)benzamide, 2-(4-fluorophenyl)-N-[4-(2-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)-2- -(2,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)ph- enyl]acetamide, 2-(4-fluorophenyl)-N-4-[2-({4-[(3-hydroxyazetidin-1-yl)carbonyl]-2-(2,2,2- -trifluoroethoxy)phenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]phenyl}ac- etamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)- phenyl]amino}[1, 2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,- 4]triazolo[1, 5-a]pyridin-6-yl)phenyl]acetamide, N-[4-(2-{[2-(2-fluoroethoxy)-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)ph- enyl]amino}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide, N-[4-(2-{[2-(2,2-difluoroethoxy)-4-(morpholin-4-ylcarbonyl)phenyl]amino}[- 1,2,4]triazolo[1, 5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(trifluoromethy- l)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylmethyl)phenyl] amino}[1, 2,4]triazolo[1,5-a] pyridin-6-yl)phenyl]acetamide, N-{4-[2-({2-ethoxy-4-[(1-methylpiperidin-4-yl)oxy]phenyl}amino)[1,2,4]tri- azolo[1,5-a]pyridin-6-yl] phenyl}-2-(4-fluorophenyl)acetamide, 2-(4-fluorophenyl)-N-{4-[2-({2-methoxy-4-[(1-methylpiperidin-4-yl)oxy]phe- nyl}amino)[1,2,4]triazolo[1, 5-a]pyridin-6-yl] phenyl}acetamide, 2-(4-fluorophenyl)-N-{4-[2-({4-[(1-methylpiperidin-4-yl)oxy]-2-(methylsul- fanyl)phenyl}amino) [1, 2,4] triazolo[1, 5-a] pyridin-6-yl] phenyl}acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylsulfonyl)phenyl]a- mino}[1, 2,4]triazolo[1,5-a] pyridin-6-yl)phenyl]acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methyl-4-(2-oxa-6-azaspiro[3.3]hept-6-ylca- rbonyl)phenyl]amino}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)phenyl]acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methyl-4-(morpholin-4-ylcarbonyl)phenyl]am- ino}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)phenyl]acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)-2- -(trifluoromethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a] pyridin-6-yl)phenyl]acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methoxy-5-(morpholin-4-ylcarbonyl)phenyl]a- mino}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)phenyl]acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methyl-6-(morpholin-4-yl)pyridin-3-yl]amin- o}[1, 2,4]triazolo[1, 5-a]pyridin-6-yl)phenyl]acetamide, 2-(4-fluorophenyl)-N-[4-(2-{[2-methyl-6-(pyrrolidin-1-yl)pyridin-3-yl]ami- no}[1, 2,4]triazolo[1, 5-a]pyridin-6-yl)phenyl]acetamide, N-{4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[1,2,- 4]triazolo[1, 5-a]pyridin-6-yl]phenyl}-2-(4-fluorophenyl)acetamide, N-(cyclopropylmethyl)-4-(2-{[2-methoxy-4-(2-oxa-6-azaspiro[3.3] hept-6-ylcarbonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzami- de, N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)pheny- l]amino}[1, 2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, 4-(2-{[2-ethoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]amino}[1,2,4]triazolo- [1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide, 4-(2-{[4-(4,5-dihydro-1,3-oxazol-2-yl)-2-methoxyphenyl]amino}[1,2,4]triaz- olo[1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide, N-(4-fluorobenzyl)-4-[2-({2-methoxy-4-[(1 S,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-ylcarbonyl] phenyl}amino)[1,2,4]triazolo[1, 5-a]pyridin-6-yl]benzamide, N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarb- onyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, N-(4-fluorobenzyl)-4-[2-({4-[(3-hydroxyazetidin-1-yl)carbonyl]-2-methoxyp- henyl}amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]benzamide, 4-[2-({4-[(1,1-dioxidothiomorpholin-4-yl)carbonyl]-2-methoxyphenyl}amino)- [1,2,4]triazolo[1,5-a]pyridin-6-yl]-N-(4-fluorobenzyl)benzamide, N-(4-fluorobenzyl)-4-[2-({4-[(4-hydroxypiperidin-1-yl)carbonyl]-2-methoxy- phenyl}amino)[1,2,4]triazolo[1, 5-a]pyridin-6-yl]benzamide, 4-[(6-{4-[(4-fluorobenzyl)carbamoyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-- 2-yl)amino]-3-methoxy-N-(oxetan-3-yl)benzamide, 4-(2-{[2-ethoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)phenyl]amino}[1- ,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide, 4-[2-({4-[(4-acetylpiperazin-1-yl)carbonyl]-2-ethoxyphenyl}amino)[1,2,4]t- riazolo[1,5-a] pyridin-6-yl]-N-(4-fluorobenzyl)benzamide, 4-[2-({2-ethoxy-4-[(3-hydroxyazetidin-1-yl)carbonyl] phenyl}amino)[1,2,4]triazolo[1, 5-a] pyridin-6-yl]-N-(4-fluorobenzyl)benzamide, N-(4-fluorobenzyl)-4-(2-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)-2-(2- ,2,2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benza- mide, N-(4-fluorobenzyl)-4-[2-({4-[(3-hydroxyazetidin-1-yl)carbonyl]-2-(2,- 2,2-trifluoroethoxy)phenyl}amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]benzam- ide, N-(4-fluorobenzyl)-4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(2, 2, 2-trifluoroethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzami- de, N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]a- mino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, 4-(2-{[4-(4-tert-butylpiperazin-1-yl)-2-methoxyphenyl]amino}[1,2,4]triazo- lo[1,5-a] pyridin-6-yl)-N-(4-fluorobenzyl)benzamide, N-(4-fluorobenzyl)-4-(2-{[2-fluoro-4-(2-oxa-6-azaspiro[3.3] hept-6-ylcarbonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzami- de, N-(4-fluorobenzyl)-4-(2-{[2-fluoro-4-(morpholin-4-ylcarbonyl)phenyl]am- ino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, 4-(2-{[2-(2, 2-difluoroethoxy)-4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,4]triazolo[- 1,5-a]pyridin-6-yl)-N-(4-fluorobenzyl)benzamide, N-(4-fluorobenzyl)-4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(trifluoromethyl)p- henyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, N-(4-fluorobenzyl)-4-[2-({2-methoxy-4-[(4-methylpiperazin-1-yl)methyl]phe- nyl}amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl] benzamide, N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylmethyl) phenyl] amino}[1, 2,4]triazolo[1, 5-a] pyridin-6-yl)benzamide, N-(4-fluorobenzyl)-4-[2-({2-methoxy-4-[(1-methylpiperidin-4-yl)oxy]phenyl- }amino)[1,2,4]triazolo[1,5-a]pyridin-6-yl]benzamide, N-(4-fluorobenzyl)-4-[2-({4-[(1-methylpiperidin-4-yl)oxy]-2-(methylsulfan- yl)phenyl}amino) [1, 2, 4] triazolo[1,5-a] pyridin-6-yl] benzamide, N-(4-fluorobenzyl)-4-(2-{[2-methyl-4-(2-oxa-6-azaspiro[3.3] hept-6-ylcarbonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzami- de, N-(4-fluorobenzyl)-4-(2-{[2-methyl-4-(morpholin-4-ylcarbonyl)phenyl]am- ino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, N-(4-fluorobenzyl)-4-(2-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarbonyl)-2-(t- rifluoromethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a] pyridin-6-yl)benzamide, N-(4-fluorobenzyl)-4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(trifluoromethoxy)- phenyl]amino}[1,2,4]triazolo[1,5-a] pyridin-6-yl)benzamide, N-(4-fluorobenzyl)-4-(2-{[2-methoxy-5-(morpholin-4-ylcarbonyl)phenyl]amin- o}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, N-(4-fluorobenzyl)-4-(2-{[2-methyl-6-(morpholin-4-yl)pyridin-3-yl]amino}l- [1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, N-(4-fluorobenzyl)-4-(2-{[2-methyl-6-(pyrrolidin-1-yl)pyridin-3-yl]amino}- l[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, 4-[2-({4-[(3-fluoroazetidin-1-yl)carbonyl]-2-methoxyphenyl}amino)[1,2,4]t- riazolo[1,5-a]pyridin-6-yl]-N-(4-fluorobenzyl)benzamide, N-(4-chlorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amin- o}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, 4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,4]triazolo[1- ,5-a]pyridin-6-yl)-N-(4-methylbenzyl)benzamide, 2-fluoro-N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)ph- enyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, 2-fluoro-N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylmethyl)phen- yl]amino}[1, 2,4]triazolo[1, 5-a] pyridin-6-yl)benzamide, N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amin- o}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)-2-methylbenzamide, N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl]a- mino}[1, 2,4]triazolo[1,5-a]pyridin-6-yl)-2-methylbenzamide, 2-chloro-N-(4-fluorobenzyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)ph- enyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, N-(4-fluorobenzyl)-2-methoxy-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)p- henyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide, N-[2-fluoro-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,- 4]triazolo[1, 5-a]pyridin-6-yl)phenyl]-2-(4-fluorophenyl)acetamide, 2-(4-fluorophenyl)-N-[5-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]a- mino}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)pyridin-2-yl]acetamide, N-[5-(2-{[2-ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,4]triazolo- [1,5-a]pyridin-6-yl)pyridin-2-yl]-2-(4-fluorophenyl)acetamide, N-(2,4-difluorobenzyl)-4-(2-{[2-methoxy-4-(2-oxo-1,3-oxazolidin-3-yl)phen- yl]amino}[1, 2,4]triazolo[1,5-a]pyridin-6-yl)-2-methylbenzamide, N-(4-fluorobenzyl)-5-(2-{[2-methoxy-4-(2-oxa-6-azaspiro[3.3]hept-6-ylcarb- onyl)phenyl]amino}[1,2,4]triazolo[1, 5-a]pyridin-6-yl)pyridine-2-carboxamide, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

8. A method of preparing a compound of general formula (I) according to claim 1, in which method an intermediate compound of general formula (5): ##STR00230## in which R.sup.1, R.sup.3, R.sup.4, and R.sup.5 are as defined for the compound of general formula (I) in claim 1, is allowed to react with a compound of general formula (5a): R.sup.2--Y (5a) in which R.sup.2 is as defined for the compound of general formula (I) in claim 1 and Y represents a leaving group, thus providing a compound of general formula (I): ##STR00231## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as defined for the compound of general formula (I) in claim 1.

9. A pharmaceutical composition comprising a compound of general formula (I) according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same, and a pharmaceutically acceptable diluent or carrier.

10. A pharmaceutical combination comprising: one or more compounds of general formula (I) according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same; and one or more agents selected from: a taxane; an epothilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2-deoxyadenosine; Thioguanine; an anti-androgen; Bortezomib; a platinum derivative; Chlorambucil; Methotrexate; and Rituximab.

11. A method for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, cervical cancer, or melanoma, comprising administering to a patient in need thereof an effective amount of a compound of general formula (I) according to claim 1, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same.

12. The pharmaceutical combination according to claim 10, in which the taxane is selected from Docetaxel and Paclitaxel.

13. The pharmaceutical combination according to claim 10, in which the epothilone is selected from Ixabepilone, Patupilone, and Sagopilone.

14. The pharmaceutical combination according to claim 10, in which the anti-androgen is selected from Flutamide, Cyproterone acetate, and Bicalutamide.

15. The pharmaceutical combination according to claim 10, in which the a platinum derivative is selected from Cisplatin and Carboplatin.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
10166149Jun 16, 2010
11167139May 23, 2011
PCT Information
PCT FiledJune 14, 2011PCT Application Number:PCT/EP2011/059806
PCT Publication Date:December 22, 2011PCT Publication Number: WO2011/157688

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
RITUXAN
rituximab
VIAL1037050011997-11-26► Subscribe Bayer Intellectual Property GmbH (Monheim, DE) Schulze; Volker (OT Bergfelde, DE), Kosemund; Dirk (Berlin, DE), Schirok; Hartmut (Langenfeld, DE), Bader; Benjamin (Berlin, DE), Lienau; Philip (Berlin, DE), Wengner; Antje Margret (Berlin, DE), Briem; Hans (Berlin, DE), Holton; Simon (Berlin, DE), Siemeister; Gerhard (Berlin, DE), Prechtl; Stefan (Berlin, DE), Koppitz; Marcus (Berlin, DE), Stockigt; Detlef (Potsdam, DE), Prien; Olaf (Berlin, DE) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Argentina081934Oct 31, 2012
Australia2011267143Jan 31, 2013
Brazil112012031837Nov 08, 2016
Canada2802629Dec 22, 2011
Chile2012003540Apr 01, 2013
China103189373Apr 06, 2016
China103189373Jul 03, 2013
Colombia6650348Apr 15, 2013
Costa Rica20120637Mar 13, 2013
Cuba20120171May 31, 2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Baxter
UBS
Dow
Boehringer Ingelheim
QuintilesIMS
Covington
Colorcon
Teva
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot